Imperial Confidence in Concept: ICiC5
Lead Research Organisation:
Imperial College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- Imperial College London (Lead Research Organisation)
- HARVARD UNIVERSITY (Collaboration)
- Oncology; Brighton and Sussex University Hospitals NHS Trust (Collaboration)
- CAMPDEN BRI (Collaboration)
- Royal Brompton Hospital (Collaboration)
- Rigshospitalet (Collaboration)
- HCI International Medical Centre (Collaboration)
- University of Warwick (Collaboration)
- Massachusetts Institute of Technology (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Wales Cancer Bank (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- AstraZeneca (Collaboration)
- Leeds General Infirmary (Collaboration)
- Derriford Hospital (Collaboration)
- Imperial College Healthcare NHS Trust (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Ossur (Collaboration)
- Domainex (Collaboration)
- Softcell Medical Ltd (Collaboration)
- St Bartholomew's Hospital (Collaboration)
- UNIVERSITY OF DUNDEE (Collaboration)
People |
ORCID iD |
Jonathan Weber (Principal Investigator) |
Publications
Rodriguez-Manzano J
(2021)
Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 Extracted RNA in under 20 min.
in ACS central science
Moniri A
(2019)
Framework for DNA Quantification and Outlier Detection Using Multidimensional Standard Curves.
in Analytical chemistry
Russell F
(2018)
A biomimicking design for mechanical knee joints.
in Bioinspiration & biomimetics
Malpartida-Cardenas K
(2019)
Quantitative and rapid Plasmodium falciparum malaria diagnosis and artemisinin-resistance detection using a CMOS Lab-on-Chip platform.
in Biosensors & bioelectronics
Rotolo A
(2018)
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
in Cancer cell
Natoli M
(2020)
Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
in Cancer Immunology, Immunotherapy
Grossman N
(2017)
Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields.
in Cell
Pavagada S
(2019)
Oligonucleotide-templated lateral flow assays for amplification-free sensing of circulating microRNAs.
in Chemical communications (Cambridge, England)
Description | The funding was used to support early-stage translational projects aimed at realising the health benefits from discoveries made by Imperial researchers. Projects ranged from experimental proof-of-concept to validation of technology. Although the funding provided to each individual project was relatively modest (from £30 to £80k), it allowed investigators to pursue focused short-term objectives critical for demonstrating whether their research could perhaps be used in future to create new treatments and vaccines or develop biomarkers and tools for predicting and monitoring disease progression or response to treatment. Importantly, although MRC CIC funding was only sufficient for around 12 awards, we successfully leveraged contributions from other sources, including Imperial's Wellcome Trust Institutional Strategic Support Fund, the NIHR Imperial Biomedical Research Centre, EPSRC and BBSRC Impact Acceleration Accounts, the Royal Marsden Hospital NHS Foundation Trust, Imperial's Higher Education Innovation Fund and from industry (AstraZeneca) to fund a total of 28 awards. This increased the impact of the MRC funding by allowing us accelerate translation of a much wider range of projects. The projects funded had diverse aims and outcomes. For example, Panetelis Georgiou and colleagues aimed to develop a cheap and easy to use device for rapid detection of influenza in developing countries. Confidence in Concept funds allowed them to design a microchip-based DNA/RNA biosensor to detect the influenza pathogen. They developed the chemistry and methods to deliver the device and validated it in the lab using clinical samples. The data generated enabled the team to secure follow-on funding to clinically validate the tools. It also paved the way for further research adapting the technology to diagnose other diseases, and lead in 2020 to the formation of a spin out company called ProtonDx, which continues to develop innovative point of care diagnostic devices. Other projects were important because they ultimately showed that potential approaches to therapy or diagnosis were not likely to work - these results are also important as they mean researchers can switch to other more promising lines of investigation. For example, Piero Posocco and team were working on a plasmonic photothermal cancer therapy using very high energy electrons but realise that simple metal nanoparticles they had planned to use were not generating enough hear so they had to explore other structures. In total, the 28 awards funded as part of this Confidence in Concept programme contributed to the formation of three spin out companies, filing of 12 patents and 53 publications. In alignment with our objective to accelerate translation of our research and increase academic-industry engagement, 16 of the 28 projects led to productive interactions/ discussion with companies, and nearly £20M of follow-on funding was obtained from a variety of sources within a few years of the award. |
Exploitation Route | The projects funded from this award have already raised almost £20M in funding from a range of sources including academic funders, industry and investors. These funders/investors aim to develop the outputs from ICiC awards into new healthcare solutions. Most notably, three new companies have been founded: NK:IO Ltd (https://nk-io.com/), ProtonDx (https://www.protondx.com/), Serg Technologies (https://sergtechnologies.com/) |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
Description | Influence on current research on cancer |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical reviews |
Impact | Sheppard et al frontiers in Immunology 2019 has been citated 30 times to date Pinato et al Oncogene 2020 has been citated 50 times to date |
Description | Schneider - ICiC 5 - Novel inhibitors |
Geographic Reach | Europe |
Policy Influence Type | Membership of a guideline committee |
URL | http://www.rcuk.ac.uk/media/news/150323/ |
Description | A carbonyl-based non-invasive test for oesophageal squamous cell carcinoma |
Amount | £167,008 (GBP) |
Funding ID | MR/S022112/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2019 |
End | 04/2021 |
Description | Confidence in Concept |
Amount | £944,000 (GBP) |
Funding ID | MC_PC_17162 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 02/2020 |
Description | Development of a cost-effective protein-based combined glycoconjugate meningococcal-pneumococcal vaccine |
Amount | £868,962 (GBP) |
Funding ID | MR/S007490/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2019 |
End | 04/2024 |
Description | Dunsby - ICiC 5 - CRUK Accelerator Award |
Amount | £4,500,000 (GBP) |
Funding ID | A29368 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2020 |
End | 02/2025 |
Description | Engineering of a multiplexed in-vitro diagnostic device for chest-pain patients |
Amount | £153,000 (GBP) |
Funding ID | M897 |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2023 |
Description | Foundation Fellow |
Amount | £1,055 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2022 |
Description | Future Vaccine Manufacturing Hub: Advancing the manufacture and deployment of cost effective vaccines |
Amount | £12,551,951 (GBP) |
Funding ID | EP/R013764/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2017 |
End | 03/2023 |
Description | ICiC 5 - Georgiou - BBSRC Responsive Mode |
Amount | £1,140,861 (GBP) |
Funding ID | BB/S005897/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2019 |
End | 02/2022 |
Description | ICiC 5 - Georgiou - Global Challenges Research Fund - UK Research and Innovation |
Amount | £144,482 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2019 |
End | 07/2020 |
Description | ICiC 5 - Georgiou - Interdisciplinary prize 2018 |
Amount | £249,765 (GBP) |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2019 |
End | 10/2022 |
Description | ICiC 5 - Georgiou - Wellcome Innovator Award |
Amount | £749,262 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2020 |
End | 04/2023 |
Description | ICiC 5 - Grossman - ICL CSC studentships |
Amount | £112,000 (GBP) |
Organisation | Imperial College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 08/2019 |
End | 09/2022 |
Description | ICiC 5 - Grossman - ICL CSC studentships |
Amount | £112,000 (GBP) |
Organisation | Imperial College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2019 |
End | 10/2022 |
Description | ICiC 5 - Guerra - CRUK Convergence Science Centre PhD studentship |
Amount | £149,769 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2020 |
End | 09/2024 |
Description | ICiC 5 - Guerra - Gustav Jonsson fellowship |
Amount | £6,000 (GBP) |
Organisation | Society of Swedish Engineers in Great Britain |
Sector | Charity/Non Profit |
Start | 01/2019 |
End | 06/2019 |
Description | ICiC 5 - Ladame - March of Dimes funding |
Amount | £108,000 (GBP) |
Funding ID | WSCR_P80733 |
Organisation | March of Dimes Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2019 |
End | 04/2022 |
Description | ICiC 5 - Maitland - Research England GCRF Internal Funding/EPSRC Global Challenges Research Funding 2016-2017 |
Amount | £85,245 (GBP) |
Funding ID | RSRO_P78428 |
Organisation | Imperial College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2018 |
End | 03/2019 |
Description | ICiC 5 - Stevens Fidler - Rapid and ultrasensitive point-of-care diagnostic test for COVID-19 |
Amount | € 580,689 (EUR) |
Funding ID | 20868 |
Organisation | EIT Health e.V. |
Sector | Private |
Country | Germany |
Start | 04/2020 |
End | 12/2020 |
Description | ICiC 5 - Tate - CRUK Convergence Science Centre - Development Fund |
Amount | £29,985 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 11/2020 |
Description | ICiC 5 - Wigneshweraraj - BBSRC Studentship |
Amount | £120,000 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2019 |
End | 04/2023 |
Description | ICiC 5 - Wigneshweraraj - MRC Studentship |
Amount | £120,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2020 |
End | 07/2023 |
Description | ICiC 5 Georgiou - NIHR Imperial BRC Infection & AMR Theme |
Amount | £125,201 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Imperial Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 03/2019 |
End | 09/2020 |
Description | IRC Next Steps Plus: A Smartphone Powered mRNA Sequence Detector |
Amount | £1,027,001 (GBP) |
Funding ID | EP/R018707/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 09/2023 |
Description | MRC Confidence in Global Nutrition |
Amount | £300,000 (GBP) |
Funding ID | MC_PC_MR/R019258/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Marie Curie Fellowship |
Amount | £184,000 (GBP) |
Organisation | Marie Curie |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2018 |
End | 09/2020 |
Description | Pathfinder Award |
Amount | £126,000 (GBP) |
Funding ID | 204592/Z/16/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Schneider - ICiC 5 - Novel inhibitors |
Amount | £4,500,000 (GBP) |
Funding ID | 205256/Z/16/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2017 |
End | 11/2019 |
Description | Schneider - ICiC 5 - Novel inhibitors |
Amount | £2,700,000 (GBP) |
Funding ID | 10638/Z/14/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2015 |
End | 05/2017 |
Description | i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance |
Amount | £4,300,620 (GBP) |
Funding ID | EP/R00529X/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 09/2024 |
Title | Cell-free, native protein expression towards a malaria parasite vaccine - ICiC 5 - Baum |
Description | A defined method for isolating and using a cell lysate from the malaria parasite that is useable for making both cytoplasmic and secreted proteins. |
Type Of Material | Technology assay or reagent |
Year Produced | 2018 |
Provided To Others? | No |
Impact | The method has also been adapted for human cell suspensions and has been successfully used for expressing SARS-CoV-2 proteins. This will be written up as a short paper and may have applications for rapid cell-free expression of viral proteins. Funding applications to further support this technology were, however, not successful. |
Description | Bhide - ICiC 5 - BSUH NHS T |
Organisation | Oncology; Brighton and Sussex University Hospitals NHS Trust |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have set-up the pilot study investigating the role of circulating HPV DNA in anal cancer. We have helped the collaborating centres set the study up at their institutions. All the samples collected for the study are analysed by the team at ICR/RMH. |
Collaborator Contribution | The partners have recruited patients to this study and have also collected and provided samples for analysis. |
Impact | N/A |
Start Year | 2017 |
Description | Bhide - ICiC 5 - ICH NHS T |
Organisation | Imperial College Healthcare NHS Trust |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have set-up the pilot study investigating the role of circulating HPV DNA in anal cancer. We have helped the collaborating centres set the study up at their institutions. All the samples collected for the study are analysed by the team at ICR/RMH. |
Collaborator Contribution | The partners have recruited patients to this study and have also collected and provided samples for analysis. |
Impact | N/A |
Start Year | 2017 |
Description | Bhide - ICiC 5 - WTB DoCO |
Organisation | Wales Cancer Bank |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have set-up the pilot study investigating the role of circulating HPV DNA in anal cancer. We have helped the collaborating centres set the study up at their institutions. All the samples collected for the study are analysed by the team at Institute of Cancer Research/Royal Marsden Hospital (ICR/RMH). |
Collaborator Contribution | The partners have recruited patients to this study and have also collected and provided samples for analysis. |
Impact | N/A |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - DT |
Organisation | Derriford Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton (Imperial) and Dr Kim (Royal Brompton). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | None yet |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - Dr MYK |
Organisation | Royal Brompton Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton (Imperial) and Dr Kim (Royal Brompton). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | NONE YET |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - Dr NWFL |
Organisation | Imperial College Healthcare NHS Trust |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton (Imperial) and Dr Kim (Royal Brompton). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | None yet |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - MHT |
Organisation | Leeds General Infirmary |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton and Dr Kim (Imperial). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | None yet |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - Prof PK |
Organisation | Imperial College Healthcare NHS Trust |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton (Imperial) and Dr Kim (Royal Brompton). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | None yet |
Start Year | 2017 |
Description | Drakakis - ICiC 5 - Design and Realisation of an Autonomic Stimulator - RH |
Organisation | St Bartholomew's Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our objective has been to develop a new, RoHS-compliant, customised, electronically-controlled and easily deployable stimulator prototype in order to detect reliably and fast which areas of the heart need ablation and thus develop, facilitate and validate an automated approach for GP localisation. The new stimulator has much superior control of the stimulation current and will help reduce GP ablation procedure time significantly. Such progress will allow for the broader investigation of the GP-based AF treatment by means of a multi-centre study we intend to lead. |
Collaborator Contribution | The Tau-20 prototype stimulator was tested in dry and wet-lab environment. A risk assessment regarding the use of the new device with the existing hospital setup has been drafted with the help of Dr Linton (Imperial) and Dr Kim (Royal Brompton)). Such a step is crucial for further characterisation and documentation of the new device (ultimately aiming at contributing to the formation of the technical file needed for CE marking). |
Impact | None yet |
Start Year | 2017 |
Description | Dunsby - ICiC 5 - High Speed Light |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | CD contributed his experience and knowhow of OPM microscopy and 3D image analysis, to the experiment design, access to his lab's existing OPM microscope and supervision of the postdoc |
Collaborator Contribution | DI carried out all sample preparation and widefield imaging. RP carried out imaging on a spinning disk confocal microscope. DI and RP both contributed to the experimental design, image and data analysis. |
Impact | None to date |
Start Year | 2017 |
Description | Georgiou - ICiC 5 - Next generation diagnostics - Prof AH |
Organisation | Imperial College London |
Department | Department of Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing the molecular methods targeting the different pathogens of interest and transferring them to our microchips. |
Collaborator Contribution | Clinical advice and samples. |
Impact | • All collaborations are multidisciplinary. • As a results of this collaboration we got two BBSRC PhD scholarships (4 years) and one MSc student working with us. |
Start Year | 2012 |
Description | Georgiou - ICiC 5 - Next generation diagnostics - Prof JB |
Organisation | Imperial College London |
Department | Department of Life Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing the molecular methods targeting the different pathogens of interest and transferring them to our microchips. |
Collaborator Contribution | Clinical advice and samples. |
Impact | • All collaborations are multidisciplinary. • As a results of this collaboration we got two BBSRC PhD scholarships (4 years) and one MSc student working with us. |
Start Year | 2016 |
Description | Georgiou - ICiC 5 - Next generation diagnostics - Prof MF |
Organisation | Imperial College London |
Department | School of Public Health |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing the molecular methods targeting the different pathogens of interest and transferring them to our microchips |
Collaborator Contribution | Clinical advice and samples. |
Impact | • All collaborations are multidisciplinary. • As a results of this collaboration we got two BBSRC PhD scholarships (4 years) and one MSc student working with us. |
Start Year | 2017 |
Description | Georgiou - ICiC 5 - Next generation diagnostics - Prof ML |
Organisation | Imperial College London |
Department | Department of Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing the molecular methods targeting the different pathogens of interest and transferring them to our microchips. |
Collaborator Contribution | Clinical advice and samples |
Impact | • All collaborations are multidisciplinary. • As a results of this collaboration we got two BBSRC PhD scholarships (4 years) and one MSc student working with us. |
Start Year | 2014 |
Description | Georgiou - ICiC 5 - Next generation diagnostics - Prof PL |
Organisation | Imperial College London |
Department | Department of Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing the molecular methods targeting the different pathogens of interest and transferring them to our microchips. |
Collaborator Contribution | Clinical advice and samples. |
Impact | • All collaborations are multidisciplinary. • As a results of this collaboration we got two BBSRC PhD scholarships (4 years) and one MSc student working with us. |
Start Year | 2016 |
Description | Grossman - ICiC 5 - Non-invasive, low-cost electrical stimulation - Harvard |
Organisation | Harvard University |
Department | Harvard Medical School |
Country | United States |
Sector | Academic/University |
PI Contribution | Our team developed the Temporal Interfering (TI) stimulation for Proof of Concept Testing |
Collaborator Contribution | Harvard: Pay for a post-doc scientist to conduct proof-of-concept testing in humans of the TI stimulation that I developed. |
Impact | Prof Alvaro Pascual-Leone (Harvard), clinical neuroscience |
Start Year | 2012 |
Description | Grossman - ICiC 5 - Non-invasive, low-cost electrical stimulation - Harvard |
Organisation | Harvard University |
Department | Harvard Medical School |
Country | United States |
Sector | Academic/University |
PI Contribution | Our team developed the Temporal Interfering (TI) stimulation for Proof of Concept Testing |
Collaborator Contribution | Harvard: Pay for a post-doc scientist to conduct proof-of-concept testing in humans of the TI stimulation that I developed. |
Impact | Prof Alvaro Pascual-Leone (Harvard), clinical neuroscience |
Start Year | 2012 |
Description | Grossman - ICiC 5 - Non-invasive, low-cost electrical stimulation - MIT |
Organisation | Massachusetts Institute of Technology |
Country | United States |
Sector | Academic/University |
PI Contribution | Grossman collaborate's with Prof Ed Boyden (MIT) Grossman sent a PhD student to Prof Ed Boyden (MIT) and co-fund a postdoc at Boyden's lab who carry key experiments in animals for him. |
Collaborator Contribution | Prof Ed Boyden (MIT) raised funding, via donation, to support the joint development work of the technology and the dissemination of the technology to labs around the world. Prof Boyden hosts a PhD from my lab (for 2 terms) and recruited a postdoc scientists to carry key experiments for us. |
Impact | Publication (https://www.ncbi.nlm.nih.gov/pubmed/28575667); Funding (donation to MIT, NIH grant under review); IP; Dr Nir Grossman, biophysics; Prof Ed Boyden (MIT), preclinical electrophys and neurotech |
Start Year | 2012 |
Description | Guerra - ICiC 5 - Collaboration with AstraZeneca |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | My research team perform experiments and generate data |
Collaborator Contribution | Intellectual contribution via discussion |
Impact | Seminar I gave to medimmune |
Start Year | 2017 |
Description | ICIC 5 - Baum - University of Dundee |
Organisation | University of Dundee |
Department | Drug Discovery Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We transferred our technology to them. |
Collaborator Contribution | They have used our technology to screen drug libraries |
Impact | There is a finished manuscript ready for submission |
Start Year | 2019 |
Description | ICiC 5 - Boutelle - Rigshospitalet, Copenhagen, Denmark |
Organisation | Rigshospitalet |
Country | Denmark |
Sector | Hospitals |
PI Contribution | We provided the monitoring system required and ran the monitoring during the protocols to obtain proof of concept data. |
Collaborator Contribution | They set up and funded the study, enabling us to collect proof of concept data. |
Impact | Publication in The Analyst |
Start Year | 2019 |
Description | ICiC 5 - Boutelle - SoftCell |
Organisation | Softcell Medical Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are currently in talks to investigate whether the combination of our technologies will be beneficial for monitoring acute compartment syndrome |
Collaborator Contribution | They already have a pH probe which has been through some proof of principle investigations and has been designed into a clinical prototype. This knowledge would be beneficial to us, as this is our next step. |
Impact | None as yet |
Start Year | 2020 |
Description | ICiC 5 - Jayasena - Effects of AZD5904 on male infertility |
Organisation | AstraZeneca |
Department | Research and Development AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Expertise in research in the fields of reproductive endocrinology and metabolism. Expertise in performing in vivo studies. |
Collaborator Contribution | Disclosure of confidential data regarding pharmacokinetics of AZD5904 compound. Free-of-charge supply of AZD5904 for the purposes of the funded experiments |
Impact | None so far, but experiments will form basis of MRC DPFS application. |
Start Year | 2017 |
Description | ICiC 5 - Ladame - Development of a paper-based device for early diagnosis of Barrett's Oesophagus |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provide the platform technology which is to be tested on ways to apply it to diagnosis of Barrett's Oesophagus |
Collaborator Contribution | Provide clinical samples for testing and validation of the device |
Impact | N/A |
Start Year | 2019 |
Description | ICiC 5 - Ladame - Development of a paper-based device for early diagnosis of Barrett's Oesophagus |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provide the platform technology which is to be tested on ways to apply it to diagnosis of Barrett's Oesophagus |
Collaborator Contribution | Provide clinical samples for testing and validation of the device |
Impact | N/A |
Start Year | 2019 |
Description | ICiC 5 - Maitland - Development of a therapeutic feeding strategy to support gut integrity in malnourished children in East Africa |
Organisation | Campden BRI |
Country | United Kingdom |
Sector | Private |
PI Contribution | Our research team has conducted the trial using the nutritional feed developed |
Collaborator Contribution | Campden BRI were contracted as a collaborative partner to develop (under our specification) the feed. Campden BRI offers a research led development of food programme which ensures safety of the final product. |
Impact | None to date |
Start Year | 2017 |
Description | ICiC 5 - Schneider - Novel inhibitors of Nemo-like kinase (NLK) to suppress cardiac muscle cell death |
Organisation | Domainex |
Country | United Kingdom |
Sector | Private |
PI Contribution | Target selection, forward plan for in-cell function and progression to small-mammal models |
Collaborator Contribution | Fragment-based screen and medicinal chemistry |
Impact | No outputs yet |
Start Year | 2017 |
Description | ICiC 5 - Vaidyanathan - Ossur corporate partnership Powered prosthetic legs |
Organisation | Ossur |
Country | Iceland |
Sector | Private |
PI Contribution | We have hired a full-time PhD student with the Ossur funding who works with Ossur on a week-to-week basis. |
Collaborator Contribution | Ossur has provided critical insight and direction towards the utility of the system to control prosthetic legs. |
Impact | Publications: F Russell, P Kormushev, R Vaidyanathan, P Ellison, "The effect of cruciate ligament laxity on a bicondylar robotic knee joint", online (print forthcoming), IEEE Transactions on Biomedical Engineering, DOI: 10.1109/TBME.2020.2971855, 12 pp, 2020 F Russell, Y Zhu, W Hey, R Vaidyanathan, P Ellison, "A novel biomimicking design for mechanical knee joints for improved mobility", Bioinspiration and Biomimetics, 13 056012, 1-12, 2018 A.H. Needham, F P Paszkiewicz, M F Md Alias, S Wilson, A A. Dehghani-Sanij, B C Khoo, R Vaidyanathan, "Subject-independent data pooling in classification of gait intent using mechanomyography on a transtibial amputee", IEEE International Conference on Robotics and Automation (ICRA), pp 1086-1811, Brisbane, Australia, May 2018 |
Start Year | 2018 |
Description | Maitland - ICiC 5 - Development of a therapeutic |
Organisation | Campden BRI |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are formally developing a prototype legume-based nutritional feeding product with a future potential to be used commercially. |
Collaborator Contribution | Campden BRI are contracted as a collaborative partner to develop the feed. Campden BRI offers a research led development of food programme which ensures safety of the final product. |
Impact | None |
Start Year | 2017 |
Description | Schneider - ICiC 5 - Novel inhibitors of Nemo-like kinase (NLK |
Organisation | Domainex |
Country | United Kingdom |
Sector | Private |
PI Contribution | Target validation by RNA interference in human pluripotent stem cell-derived cardiomyocytes, assay development, mouse microsurgery and physiology, phosphoproteomics, 3D engineered heart tissue |
Collaborator Contribution | Medicinal chemistry, structural biology, computer-aided drug design |
Impact | UK composition of matter patent application, submitted October 2017. Cell Stem Cell manuscript, in revision. |
Start Year | 2013 |
Description | Tate - ICiC 5 - Disarming the Hedgehog - Dundee |
Organisation | University of Dundee |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I/Imperial have led the collaboration, initiated the proposal to undertake and HTS, and bring most of the technologies required (assay, reagents). |
Collaborator Contribution | Provided the screening platform and access to 80,000 compounds for screening |
Impact | N/A |
Start Year | 2018 |
Description | Tate - ICiC 5 - Disarming the Hedgehog - ICR |
Organisation | Institute of Cancer Research UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I/Imperial have led the collaboration, initiated the proposal to undertake and HTS, and bring most of the technologies required (assay, reagents) |
Collaborator Contribution | Involved in screening co-culture and spheroid models of PDAC and other cancers of severe unmet need. |
Impact | N/A |
Start Year | 2017 |
Description | Tate - ICiC 5 - Disarming the Hedghog - Oxford |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I/Imperial have led the collaboration, initiated the proposal to undertake and HTS, and bring most of the technologies required (assay, reagents). |
Collaborator Contribution | Oxford University provided the protein for the assay |
Impact | N/A |
Start Year | 2016 |
Description | Vaidyanathan - ICiC 5 - HCI |
Organisation | HCI International Medical Centre |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Our team will be traveling to HCI (in Glasgow) |
Collaborator Contribution | In addition to equipment and funds, HCI have lent their expertise in their domain of assistive technology. |
Impact | None yet |
Start Year | 2017 |
Description | Vaidyanathan - ICiC 5 - Ossur |
Organisation | Ossur |
Country | Iceland |
Sector | Private |
PI Contribution | Our team will be traveling to Ossur (in Iceland) to test our robotic system |
Collaborator Contribution | In addition to equipment and funds, Ossur have lent their expertise in the domain of assistive technology. |
Impact | None yet |
Start Year | 2017 |
Description | Wigneshweraraj - ICiC 5 - Prof Jaramillo - University of Warwick |
Organisation | University of Warwick |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The phage-derived toxic payloads and their bacterial target are well characterised by Prof Wigneshweraraj and his team at Imperial |
Collaborator Contribution | Prof Jaramillo is providing expert advice on the biology of the P2 phage used for making synthetic viruses. Prof Wigneshweraraj provides expert advice on bacteriology, antibacterials and phage biology. |
Impact | N/A - Too early |
Start Year | 2017 |
Title | DEVICES AND METHOD FOR DETECTING AN AMPLIFICATION EVENT |
Description | A method is disclosed herein for detecting an amplification reaction in a solution containing a biological sample using an array of ion sensors. The amplification reaction is indicative of the presence of a nucleic acid. The method comprises monitoring a signal from each respective sensor of the array of ion sensors, detecting a change in the signal from a first sensor of the array of ion sensors, and comparing the signal from the first sensor with the signal of at least one neighbouring sensor, the at least one neighbouring sensor being proximate to the first sensor in the array. The method further comprises determining, based on the comparing, that an amplification event has occurred in the solution in the vicinity of the first sensor. |
IP Reference | WO2019234451 |
Protection | Patent application published |
Year Protection Granted | 2019 |
Licensed | No |
Impact | N/A |
Title | METHOD FOR DETECTING A SINGLE NUCLEOTIDE POLYMORPHISM (SNP) USING LAMP AND BLOCKING PRIMERS |
Description | The present application relates to methods for detecting a first allele of a single nucleotide polymorphism (SNP) in a nucleic acid sequence under isothermal conditions using primers specific for said first allele, in particular using Loop mediated isothermal amplification (LAMP), wherein the amplification of a second allele is prevented by using blocking primers. |
IP Reference | WO2019234251 |
Protection | Patent application published |
Year Protection Granted | 2019 |
Licensed | No |
Impact | N/A |
Title | METHOD FOR DETECTING A TANDEM REPEAT |
Description | The present application relates to methods for detecting a tandem repeat in a nucleic acid sequence under isothermal conditions using primers. |
IP Reference | WO2019234252 |
Protection | Patent application published |
Year Protection Granted | 2019 |
Licensed | No |
Impact | N/A |
Title | NATURAL KILLER CELLS |
Description | This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production. |
IP Reference | WO2020002911 |
Protection | Patent granted |
Year Protection Granted | 2020 |
Licensed | No |
Impact | N/A |
Title | ICiC 5 - Stevens Fidler - Point-of-care diagnostic for Covid-19 |
Description | We are developing a point-of-care lateral flow assay, similar to a pregnancy test, for the early detection of Covid-19 that could be used for asymptomatic and very early diagnostic. This technology would fill the current gap between the PCR based nucleic acid test that requires specialised equipment and trained personnel, and the point-of-care antibody test that is not suitable for early diagnostic. We are currently developing a device prototype and have partnered with clinical collaborators for assay validation. |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2022 |
Development Status | Under active development/distribution |
Impact | N/A |
Company Name | NK:IO |
Description | NK:IO develops new immunotherapeutic approaches, leveraging the power of natural killer cells. |
Year Established | 2020 |
Impact | Exploiting our pioneering discoveries in small molecule and peptide ligand activation of blood stem cell progenitors, NK:IO's platform technologies offer the potential for greatly enhanced NK cell expansion and tumour killing capacity in the field of NK cell-based therapy for cancer. wNK:IO Cells Using umbilical cord blood as a source of blood stem cells, we have produced first-generation wNK:IO human NK cells for cancer immunotherapy. The synergistic combination of a small molecule antagonist and recombinant protein ligand provides the basis for dramatically enhanced NK cell expansion for use as a cell therapy. The wNK:IO cells generated are highly functional and do not exhibit the 'exhaustion' phenotype that limits the efficacy of competitor NK cell technologies. eNK:IO Cells While our enhanced expansion methodology will allow us to improve and expand the use of NK cell therapies, it is likely, for certain hard to treat cancer subtypes, that cell engineering will be required to increase the therapeutic effect. Our next generation engineered eNK:IO human NK cells have been produced by deleting relevant inhibitory receptors on the cell surface prior to differentiation to mature NK cells. These engineered "super" NK cells exhibit enhanced cytotoxic and tumour cell-sensing properties. dNK:IO REV-ERB Antagonists We have leveraged the validated biological mechanism in our NK cell expansion technologies to develop a novel series of small molecules. The dNK:IO platform can be used to significantly mobilise and enhance NK cell production in vivo. This ability to produce large numbers of NK cells on demand represents a highly novel approach, with significant potential implications for the immune system's ability to carry out anti-tumour responses as well as tackle long-term pathogen infection. |
Website | https://nk-io.com/ |
Company Name | ProtonDx |
Description | ProtonDx develops a diagnostic device for COVID-19 |
Year Established | 2020 |
Impact | Earlier this year, we launched the Dragonfly Diagnostic Platform, a rapid, portable, and accurate diagnostic product. ? Dragonfly combines portability, speed, high sensitivity, high specificity, and convenience to differentiate and detect multiple pathogens from a single sample in less than 30 minutes. ? High quality DNA and RNA samples are extracted from nasopharyngeal swabs and prepared for testing with minimal handling, providing results equivalent to the 'gold standard' polymerase chain reaction test (PCR) at point of need. In addition, the Dragonfly platform provides confidence that the patient sample has been taken and tested correctly. ? Dragonfly test panels are available to detect a variety of pathogens. ? The Dragonfly system is a CE marked in vitro diagnostic medical device and complies with the current European In vitro Diagnostic Devices Directive (IVDD 98/79/EC). ? The latest news of Dragonfly being used at the Commonwealth Games 2022 can be found here |
Website | http://protondx.com |
Company Name | SERG Technologies |
Description | SERG Technologies develops wearable technology designed to analyse subconscious muscle contractions in order to meet a range of applications, such as smart prosthetics and controlling TVs. |
Year Established | 2019 |
Impact | Our PD.Ignite platform is the first of its kind to connect stakeholders within one platform whilst providing continuous monitoring for Parkinson's Disease. Using our patented PD.Ignite wearables and dashboard enables remote continuous monitoring of the motor and non-motor Parkinsonian symptoms (tremor, rigidity, slowness of movement, heart rate, sleep etc), generating patient-specific symptom analytics. These analytics support people with Parkinson's in unlocking personalised care, management and treatment optimisation which can improve their quality of life, give greater control and efficiency for healthcare providers. To further support our research, we have acquired a research space that is used as an additional research site and allows our participants to fully immerse themselves in our research and development trials. The following trials are being conducted: Wearable technology to measure movement symptoms in people with PD; Closed-loop rehabilitation for PD and wider neurological disorders; SERG-ONE - An MMG Sensor Platform to optimise therapy for PD; SERG ONE DBS - MMG for precise, DBS parametrisation to treat PD; Closed-Loop Electronic Stimulation for Passive Tremor Suppression. |
Website | https://sergtechnologies.com/ |
Description | Hanna - ICiC 5 - Imperial Festival |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Undergraduate students |
Results and Impact | Participation in the Imperial Festival |
Year(s) Of Engagement Activity | 2017 |
Description | ICiC 5 - Dunsby - Invited presentation by Chris Dunsby at the NanoBioTech conference, Montreux, 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Presented results of research to an interdisciplinary audience spanning Engineering, Biology, Chemistry and Physics. |
Year(s) Of Engagement Activity | 2020 |
URL | http://www.nanotech-montreux.com |
Description | ICiC 5 - Dunsby - Invited seminar presentation by Chris Dunsby at Charles River Laboratories, Chesterford Research Park, 2020. |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Disseminated results of research and potential future opportunities to industry |
Year(s) Of Engagement Activity | 2020 |
Description | ICiC 5 - Karadimitris - 2018: Imperial NIHR BRC open day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | 2018: Imperial NIHR BRC open day Our work on cancer immunotherapy was presented in an interactive mode in this open day attended by >100 people |
Year(s) Of Engagement Activity | 2018 |
Description | ICiC 5 - Karadimitris - 2019: A press release issued by ICL |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 2019: A press release issued by ICL to highlight the advances in cancer immunotherapy described in a publication from my group. The press release was published in the UK national press and by several media outlets across Europe |
Year(s) Of Engagement Activity | 2019 |
Description | ICiC 5 - Tate - Imperial Festival |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The Imperial Festival attracts ~20,000 visitors from the general public, schools and interested third parties. The purpose is to engage wider audiences, broaden understanding of the research that is going on in the college, and encourage interest in STEM research. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.imperial.ac.uk/festival/ |
Description | ICiC5 - Dunsby - Invited talk at SLAS 2019 conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Invited talk at SLAS 2019 conference - follow up invitation to present work at NanoBioTech 2019 conference resulted. Also gained requests to collaborate - samples will be shipped to Imperial. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.slas2019.org/program/slas2019-scientific-podium-program/ |
Description | Miguel Aliaga, ICiC 5 - The use of innovative spectroscopy technologies (i-Knife and DESI) - George Freeman |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Policymakers/politicians |
Results and Impact | Hosted Minister for Life Sciences George Freeman during his visit to LMS. In the lab, we showed him how flies can be used to study obesity and cancer and discussed the importance of model organisms for biomedical research. |
Year(s) Of Engagement Activity | 2016 |
Description | Miguel-Aliaga - ICiC 5 - GF |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Policymakers/politicians |
Results and Impact | Hosted Minister for Life Sciences George Freeman during his visit to LMS. In the lab, we showed him how flies can be used to study obesity and cancer and discussed the importance of model organisms for biomedical research. |
Year(s) Of Engagement Activity | 2016 |
URL | https://lms.mrc.ac.uk/ministerial-visit-gets-hearts-racing/ |
Description | Miguel-Aliaga, ICiC 5 - The use of innovative spectroscopy technologies (i-Knife and DESI) - BBC Radio 4 interview |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | I contributed to BBC Radio 4's "Inside Science" series |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.bbc.co.uk/programmes/b0713p30 |
Description | Miguel-Aliaga, ICiC 5 - The use of innovative spectroscopy technologies (i-Knife and DESI) - Brainy Tongue |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | 1. Neurogastronomy workshop with world-renowned chefs and neurobiologists. This has resulted in a network of collaborators, with whom I will continue to develop initiatives e.g. a follow up event based on our current dialogue with Heston Blumenthal and his team on the links between the intestine and emotion. |
Year(s) Of Engagement Activity | 2014,2016 |
URL | http://www.bbc.co.uk/news/business-37800097 |
Description | Miguel-Aliaga, ICiC 5 - The use of innovative spectroscopy technologies (i-Knife and DESI) - IF: Food of Tomorrow |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Undergraduate students |
Results and Impact | My lab had a stand at the Imperial Fringe. This event was about the future of food and how we will feed the next generation. We will continue to participate in similar events. |
Year(s) Of Engagement Activity | 2006,2016 |
Description | Miguel-Aliaga, ICiC 5 - The use of innovative spectroscopy technologies (i-Knife and DESI) - Social Media (Twitter) |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | I regularly liaise with our Institute's press office and use social media (>780 followers) |
Year(s) Of Engagement Activity | 2016,2017,2018 |
URL | https://twitter.com/flygutlab?lang=en |
Description | Vaidyanathan - ICiC 5 - Interview for National Film |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | The Royal Academy of Engineering has made a film "This is Engineering" to promote interest in children to consider engineering as a career. The film featured 5 engineers in the country selected whose work would be highlighted. Mr Chris Caulcrick, a student working on the project "Mechanomyography control of lower limb prosthetics" was selected as one of the featured engineers. A range of film clips of him working are shown on the RAEng site along with interviews discussing the project. |
Year(s) Of Engagement Activity | 2018 |
URL | https://www.youtube.com/watch?v=DlwHeT-Cutk&feature=youtu.be |